000903019 001__ 903019
000903019 005__ 20240308203405.0
000903019 0247_ $$2doi$$a10.3390/cancers13236030
000903019 0247_ $$2Handle$$a2128/30108
000903019 0247_ $$2pmid$$a34885141
000903019 0247_ $$2WOS$$aWOS:000734552300001
000903019 037__ $$aFZJ-2021-04748
000903019 082__ $$a610
000903019 1001_ $$0P:(DE-Juel1)186984$$aKrämer, Felicia$$b0
000903019 245__ $$aEvaluation of 3-l- and 3-d-[18F]Fluorophenylalanines as PET Tracers for Tumor Imaging
000903019 260__ $$aBasel$$bMDPI$$c2021
000903019 3367_ $$2DRIVER$$aarticle
000903019 3367_ $$2DataCite$$aOutput Types/Journal article
000903019 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1641912344_25030
000903019 3367_ $$2BibTeX$$aARTICLE
000903019 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000903019 3367_ $$00$$2EndNote$$aJournal Article
000903019 520__ $$aPurpose: The preclinical evaluation of 3-l- and 3-d-[18F]FPhe in comparison to [18F]FET, an established tracer for tumor imaging. Methods: In vitro studies were conducted with MCF-7, PC-3, and U87 MG human tumor cell lines. In vivo µPET studies were conducted in healthy rats with/without the inhibition of peripheral aromatic l-amino acid decarboxylase by benserazide pretreatment (n = 3 each), in mice bearing subcutaneous MCF-7 or PC-3 tumor xenografts (n = 10), and in rats bearing orthotopic U87 MG tumor xenografts (n = 14). Tracer accumulation was quantified by SUVmax, SUVmean and tumor-to-brain ratios (TBrR). Results: The uptake of 3-l-[18F]FPhe in MCF-7 and PC-3 cells was significantly higher relative to [18F]FET. The uptake of all three tracers was significantly reduced by the suppression of amino acid transport systems L or ASC. 3-l-[18F]FPhe but not 3-d-[18F]FPhe exhibited protein incorporation. In benserazide-treated healthy rats, brain uptake after 42–120 min was significantly higher for 3-d-[18F]FPhe vs. 3-l-[18F]FPhe. [18F]FET showed significantly higher uptake into subcutaneous MCF-7 tumors (52–60 min p.i.), while early uptake into orthotopic U87 MG tumors was significantly higher for 3-l-[18F]FPhe (SUVmax: 3-l-[18F]FPhe, 107.6 ± 11.3; 3-d-[18F]FPhe, 86.0 ± 4.3; [18F]FET, 90.2 ± 7.7). Increased tumoral expression of LAT1 and ASCT2 was confirmed immunohistologically. Conclusion: Both novel tracers enable accurate tumor delineation with an imaging quality comparable to [18F]FET.
000903019 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000903019 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000903019 7001_ $$0P:(DE-Juel1)180812$$aGröner, Benedikt$$b1$$ufzj
000903019 7001_ $$0P:(DE-Juel1)180770$$aHoffmann, Chris$$b2$$ufzj
000903019 7001_ $$0P:(DE-Juel1)176281$$aCraig, Austin$$b3
000903019 7001_ $$0P:(DE-Juel1)131826$$aBrugger, Melanie$$b4
000903019 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b5
000903019 7001_ $$0P:(DE-HGF)0$$aTimmer, Marco$$b6
000903019 7001_ $$0P:(DE-Juel1)175142$$aNeumaier, Felix$$b7
000903019 7001_ $$0P:(DE-Juel1)176188$$aZlatopolskiy, Boris D.$$b8
000903019 7001_ $$0P:(DE-Juel1)180330$$aEndepols, Heike$$b9
000903019 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b10$$eCorresponding author
000903019 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers13236030$$gVol. 13, no. 23, p. 6030 -$$n23$$p6030 -$$tCancers$$v13$$x2072-6694$$y2021
000903019 8564_ $$uhttps://juser.fz-juelich.de/record/903019/files/cancers-13-06030.pdf$$yOpenAccess
000903019 8767_ $$d2024-03-08$$eAPC$$jZahlung erfolgt$$zOABLE Report 03/24
000903019 909CO $$ooai:juser.fz-juelich.de:903019$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$popenCost$$pdnbdelivery
000903019 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180812$$aForschungszentrum Jülich$$b1$$kFZJ
000903019 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180770$$aForschungszentrum Jülich$$b2$$kFZJ
000903019 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131826$$aForschungszentrum Jülich$$b4$$kFZJ
000903019 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b5$$kFZJ
000903019 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)175142$$aForschungszentrum Jülich$$b7$$kFZJ
000903019 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180330$$aForschungszentrum Jülich$$b9$$kFZJ
000903019 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b10$$kFZJ
000903019 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000903019 9141_ $$y2021
000903019 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2019$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000903019 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000903019 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000903019 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2019$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000903019 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000903019 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000903019 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000903019 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000903019 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000903019 920__ $$lyes
000903019 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000903019 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
000903019 9801_ $$aFullTexts
000903019 980__ $$ajournal
000903019 980__ $$aVDB
000903019 980__ $$aUNRESTRICTED
000903019 980__ $$aI:(DE-Juel1)INM-5-20090406
000903019 980__ $$aI:(DE-Juel1)INM-2-20090406
000903019 980__ $$aAPC